Alvotech (ALVO)
4.87
+0.01
(+0.21%)
USD |
NASDAQ |
Nov 09, 09:53
Alvotech Enterprise Value : 3.043B for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 3.043B |
| November 05, 2026 | 2.933B |
| November 04, 2026 | 2.975B |
| November 03, 2026 | 2.929B |
| November 02, 2026 | 2.908B |
| October 30, 2026 | 2.968B |
| October 29, 2026 | 3.054B |
| October 28, 2026 | 3.072B |
| October 27, 2026 | 3.004B |
| October 26, 2026 | 2.958B |
| October 23, 2026 | 2.943B |
| October 22, 2026 | 3.018B |
| October 21, 2026 | 3.140B |
| October 20, 2026 | 3.136B |
| October 19, 2026 | 3.104B |
| October 16, 2026 | 3.093B |
| October 15, 2026 | 3.204B |
| October 14, 2026 | 3.154B |
| October 13, 2026 | 3.229B |
| October 12, 2026 | 3.272B |
| October 09, 2026 | 3.371B |
| October 08, 2026 | 3.332B |
| October 07, 2026 | 3.396B |
| October 06, 2026 | 3.500B |
| October 05, 2026 | 3.489B |
| Date | Value |
|---|---|
| October 02, 2026 | 3.254B |
| October 01, 2026 | 3.314B |
| September 30, 2026 | 3.379B |
| September 29, 2026 | 3.421B |
| September 28, 2026 | 3.503B |
| September 25, 2026 | 3.361B |
| September 24, 2026 | 3.407B |
| September 23, 2026 | 3.382B |
| September 22, 2026 | 3.393B |
| September 21, 2026 | 3.407B |
| September 18, 2026 | 3.404B |
| September 17, 2026 | 3.214B |
| September 16, 2026 | 3.129B |
| September 15, 2026 | 3.100B |
| September 14, 2026 | 3.111B |
| September 11, 2026 | 3.197B |
| September 10, 2026 | 3.179B |
| September 09, 2026 | 3.168B |
| September 08, 2026 | 3.161B |
| September 04, 2026 | 3.207B |
| September 03, 2026 | 3.229B |
| September 02, 2026 | 3.214B |
| September 01, 2026 | 3.179B |
| August 31, 2026 | 3.161B |
| August 28, 2026 | 3.075B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 506.92M |
| Amgen, Inc. | 289.86B |
| Regeneron Pharmaceuticals, Inc. | 86.90B |
| Anika Therapeutics, Inc. | 176.07M |
| BioCryst Pharmaceuticals, Inc. | 2.422B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -66.82M |
| Revenue (Quarterly) | 105.77M |
| Total Expenses (Quarterly) | 172.59M |
| EPS Diluted (Quarterly) | -0.1873 |
| Gross Profit Margin (Quarterly) | 50.65% |
| Profit Margin (Quarterly) | -63.17% |
| Earnings Yield | -11.45% |
| Operating Earnings Yield | 2.85% |
| Normalized Earnings Yield | -11.45 |